EPISODE · May 6, 2025 · 5 MIN
Revisiting the SUMMIT Trial | JACC Deep Dive
from JACC This Week
This JACC Deep Dive in our May 13 issue highlights new findings from the SUMMIT CKD study, showing that terzepatide improves symptoms, function, and weight in patients with HFpEF and obesity—regardless of kidney function. The analysis also underscores the importance of using both creatinine and cystatin C to better assess kidney health. Reviewers praised the study's methodological rigor and dual focus, while noting the need for larger, long-term trials to confirm renal outcomes.
NOW PLAYING
Revisiting the SUMMIT Trial | JACC Deep Dive
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 3, 2026 ·44m
Feb 21, 2026 ·30m
Jan 2, 2026 ·47m